The Brown University Child and Adolescent Psychopharmacology Update This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Research Roundup
Consult reduces antipsychotic utilization in child Medicaid Proposed budget would slash NIH funding Risk factors for suicide differ in children (maltreatment) and adolescents (depression) Studies show 3%–26% of people on long‐term Rx opioids for pain develop OUDs CDC sees fentanyl and heroin increasing as drivers in OD epidemic (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - April 24, 2017 Category: Psychiatry Tags: Research Roundup Source Type: research

Relatively young patients develop antipsychotic ‐related movement disorders
Little is known about the impact of antipsychotic medication on movement disorders in young patients a few years after disease onset, but a recent study shows a surprisingly high rate of such disorders in young people only four years after the onset of the disease. Researchers used the Genetic Risk and Outcome of Psychosis (GROUP) study to assess the prevalence, incidence, persistence, and clinical correlates of drug‐related movement disorders on young patients. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - April 24, 2017 Category: Psychiatry Tags: What's New in Research Source Type: research

Where pediatric irritability research is now, and where it needs to go
Irritability, a common problem in youth, is an “increased propensity to exhibit increased anger relative to one's peers,” writes Ellen Leibenluft, M.D., senior investigator and chief of the Section on Mood Dysregulation and Neuroscience and co‐branch chief of the Emotion and Development Branch at the National Institute of Mental Health Intramural Research Program. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - April 24, 2017 Category: Psychiatry Tags: Irritability Source Type: research

Perinatal depression not linked to child problems when results adjusted for familial confounders
Maternal prenatal and postpartum depression have been linked to child behavior problems, but these problems are more likely due to familial factors, researchers have found. This was the first large‐scale longitudinal study to adjust results for confounding using a sibling model. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - March 27, 2017 Category: Psychiatry Tags: Maternal Depression Source Type: research

Recent labeling changes for Vyvanse and Latuda
Recently, the federal Food and Drug Administration approved a labeling change for the Vyvanse chewable tablet (lisdexamfetamine), a stimulant indicated to treat attention‐deficit hyperactivity disorder in children ages 6 to 17 years. The new labeling states: Vyvanse chewable tablets must be chewed thoroughly before swallowing. Vyvanse capsules can be substituted with Vyvanse chewable tablets on a unit per unit/mg per mg basis (for example, 30 mg capsules for 30 mg chewable tablet). This is a new formulation. The change was issued Jan. 28. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - March 27, 2017 Category: Psychiatry Tags: From the FDA Source Type: research

Research Roundup
Child maltreatment contributes to learning and behavior problems Brain volume increases, decreases differ in anxiety, bipolar disorders State considers firing Oregon insurers for denying autism coverage (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - March 27, 2017 Category: Psychiatry Tags: Research Roundup Source Type: research

FDA sets public meeting and requests comment on autism medication development
The Food and Drug Administration (FDA) has announced the opportunity for public comment on Patient‐Focused Drug Development for autism. The public meeting is intended to allow the FDA to obtain patient perspectives on the impact of autism on daily life as well as patient views on treatment approaches for autism. The public meeting will be held on May 4, 2017, from 1 to 5 p.m. at the FDA's White Oak Campus in Silver Spring, Maryland. Registration to attend the meeting must be received by April 24. Electronic comments must be submitted on or before July 5. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - March 27, 2017 Category: Psychiatry Tags: News Source Type: research

Telepsychiatry partnership aims to improve care, reduce costs
Observing the growing importance of telepsychiatry as a means of providing mental health services to consumers in underserved communities, the National Council for Behavioral Health and a provider of psychiatric telehealth services for adolescents and adults announced a partnership March 14 that company officials say will improve patient outcomes and lower health care costs. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - March 27, 2017 Category: Psychiatry Tags: News Source Type: research

The earlier the exposure, the more serious the adult sequelae of adolescent cannabis use
Exposure to cannabis in adolescence is associated with possible harmful cognitive and affective outcomes in adulthood, researchers have found. A literature search examining the potential effects of exposure to cannabis and related synthetic cannabinoids during adolescence has found that regardless of whether cannabis causes these consequences, youth who are exposed are also at higher risk for potential psychiatric morbidity and learning problems, as well as suicidality and addiction as adults. The earlier the onset of cannabis use, the higher the risk for problems in adulthood, according to the study. (Source: The Brown Un...
Source: The Brown University Child and Adolescent Psychopharmacology Update - March 27, 2017 Category: Psychiatry Tags: What's New in Research Source Type: research

Don't overlook malpractice liability in medical marijuana states
It is an untapped frontier of case law that likely won't go untested much longer, now that more than half of the states allow for some medical uses of marijuana. Are physicians being exposed to significant malpractice liability when certifying patients to receive marijuana for medical purposes? (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - March 27, 2017 Category: Psychiatry Tags: Marijuana Source Type: research

Naltrexone during pregnancy being considered due to prenatal opioid exposure
The federal government is considering balancing the risks of naltrexone administered during pregnancy with the risks of neonatal abstinence syndrome (NAS). The Substance Abuse and Mental Health Services Administration (SAMHSA) has released a draft of its report to Congress on prenatal opioid exposure and NAS. The draft was published in the Jan. 19 Federal Register, and was open for public comment until Feb. 21. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - February 24, 2017 Category: Psychiatry Tags: Substance Use Disorders Source Type: research

Belladonna found in certain homeopathic teething tablets
The U.S. Food and Drug Administration announced Jan. 29 that its laboratory analysis found inconsistent amounts of belladonna, a toxic substance, in certain homeopathic teething tablets, sometimes far exceeding the amount claimed on the label. The agency is warning consumers that homeopathic teething tablets containing belladonna pose an unnecessary risk to infants and children and urges consumers not to use these products. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - February 23, 2017 Category: Psychiatry Tags: From the FDA Source Type: research

Research Roundup
Subthreshold BD, not ADHD, more likely linked to nicotine dependence in teens Predictors of and problems associated with low language at age 7 Brain enlargement in high‐risk infants may predict autism diagnosis at 2 years of age (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - February 23, 2017 Category: Psychiatry Tags: Research Roundup Source Type: research

Recommendations for protecting infants from NAS: Draft report
Below are the key recommendations in the draft report prepared by the Substance Abuse and Mental Health Services Administration (SAMHSA) in response to the Protecting Our Infants Act (see related story, p. 1). (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - February 23, 2017 Category: Psychiatry Tags: News Source Type: research

GAO calls for more collaboration to reduce inappropriate psychotropic medications in foster care
The most recent Government Accountability Office (GAO) report on the use of psychotropic medications for children in foster care focuses on the need for collaboration between agencies to make sure such medication use is appropriate. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - February 23, 2017 Category: Psychiatry Tags: What's New in Research Source Type: research